ClaudioAnasettiMD

Oncology • Tampa, FL

Professor, Oncologic Sciences, USF-Morsani

Join to view full profile

Dr. Anasetti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anasetti's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
# Mcc-Fa
Tampa, FL 33612
Phone+1 813-745-2720

Fax+1 813-745-6855

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1983 - 1989
University of WashingtonResidency, Pediatrics, 1982 - 1983
University of Perugia Faculty of MedicineClass of 1980

Certifications & Licensure

OR State Medical License 1988 - Present
FL State Medical License 2004 - 2027
OK State Medical License 1982 - 1984
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer Start of enrollment: 1990 Aug 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Start of enrollment: 1995 Jul 01
Completed
Phase 2
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 2
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p> Start of enrollment: 1996 Mar 01
Completed
Phase 2
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Start of enrollment: 2001 Oct 01
Completed
Phase 2
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
Completed
Phase 1, Phase 2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant Start of enrollment: 2013 May 14
Completed
Phase 3
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes Start of enrollment: 2015 May 01
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
Blood. 2024-11-28
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukem...
Omar Albanyan, Hany Elmariah, Denise Kalos, Jongphil Kim, Rawan Faramand
Transplantation and Cellular Therapy. 2024-11-01
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosp...
Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan
Transplantation and Cellular Therapy. 2024-10-01

Journal Articles

Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology

Abstracts/Posters

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia
Claudio Anasetti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Mayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013
Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Mayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013

Press Mentions

Leading Bone Marrow Transplant Expert Recommends Significant Change to Current PracticeOctober 17th, 2012
Researchers Find Regulatory T-cell Clue to Help Prevent GVHDNovember 28th, 2011